Rosatom has initiated the creation of an international platform for the development of radiopharmaceuticals based on terbium-161, which can improve the effectiveness of cancer treatment and reduce the side effects of therapy. This was announced at the "World Nuclear Week" forum.
We propose to form a multinational expert group that will combine technologies for the production of the radionuclide, methods for its purification, the development of promising radiopharmaceuticals, and the exchange of clinical results
The project is designed for three years with the possibility of extension and includes regular publication of results in peer-reviewed scientific journals.
Technologies used for the production and use of lutetium-177 can be adapted for terbium-161. The additional effect of terbium-161 electrons allows to increase the effectiveness of therapy with minimal damage to healthy tissues.
The scientific division of Rosatom manages 12 research centers, nine reactors, and more than 700 experimental facilities, and produces over ten radiopharmaceuticals. A large radiopharmaceutical plant is under construction in Obninsk, scheduled to launch next year.
Read more on the topic:
Now on home
Start of deliveries scheduled for 2027
Over 51,000 new motorcycles were sold in Russia in 2025
The car will take at least a year to assemble
The application's audience has reached 20 million users
The model will be included in the list of cars for taxis, price - from 2.25 million rubles
All parking lots of the "Administrator of the Moscow Parking Space" are connected to the service
The cars will be supplied to the Moscow Transport Service Directorate
Deliveries to India may begin in 2028
The technology provides automated search for all types of defects in power units
The plane flew 500 km, accelerating to 425 km/h
The plant stated that the information about the termination of purchases for models 6 and 8 is not true
Scientists are using the "Ekran-M" installation